IMI2 – Call 7

IMI2 – Call 7 was launched on 18 December 2015 with the following topics:

  • Validation of translational imaging methods in drug safety assessment (TRISTAN)
  • Identification of druggable targets modulating misfolded proteins in Alzheimer’s and Parkinson’s diseases
  • Pathological neuron-glia interactions in neuropathic pain
  • Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention
  • A comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer
  • Coordination and support action (CSA) for the big data for better outcomes programme
    (part of the IMI Big Data for Better Outcomes (BD4BO) programme)
  • Increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients
    (part of the IMI Big Data for Better Outcomes (BD4BO) programme)

More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents, including documents for applicants, the list of expert reviewers, and the independent observers’ reports of the evaluations, can be found on the IMI2 Call documents page.



The projects resulting from IMI2 – Call 7 are:

  • BigData@Heart – Big data at heart
  • DO->IT - Big data for better outcomes, policy innovation and healthcare system transformation
  • IB4SD-TRISTAN - Imaging biomarkers for safer drugs: validation of translational imaging methods in drug safety assessment
  • IMPRiND - Inhibiting misfolded protein propagation in neurodegenerative diseases
    factsheet | website
  • ITCC-P4 -- ITCC pediatric preclinical POC platform
  • NGN-PET - Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments


Proposal submission information

  • Proposals submitted: 32
  • Inadmissible & ineligible proposals: 0
  • Proposals recommended for funding: 7
  • Proposals not recommended for funding: 25